This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

24 Nov 2021

WuXi Biologics' MFG5 facility completes first GMP production at 24,000-L line

The facility's total 60,000-L capacity supports growing demand for manufacture of late-phase and commercial projects

Building on the success of intiating GMP operations of the 36,000-L biomanufacturing line of its drug substance facility MFG5 in February this year, China's WuXi Biologics has now completed the first GMP production at the facility's new 24,000-L line.

The new line combines 12 x 2000-L single-use bioreactors to enable various production processes — including fed-batch, perfusion and concentrated fed-batch — at different scales, ranging from 2,000 L to 12,000 L.

According to the company, implementing WuXiUP ― a continuous manufacturing bioprocessing platform based on intensified perfusion culture processes ― in the 24,000-L line for commercial production will allow MFG5 to increase productivity and reduce cost of goods sold.

Now, with its total 60,000-L capacity, MFG5 will further support growing demand for the manufacture of late-phase and commercial projects across multiple modalities, such as monoclonal antibodies, bispecifics and fusion proteins, the company said.

As a result, there is a total of approximately 150,000L biomanfacturing capacity at WuXi Biologics, which makes the company one of the largest cGMP biologics manufacturing facilities in the world to employ only single-use bioreactors.

Dr Chris Chen, CEO of WuXi Biologics said the rapidly growing demand from global companies for commercial manufacturing is due to the "success of our ‘follow and win-the-molecule’ strategy".

Related News